Transgene’s board of directors strengthens its governance
Category: Press release
Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
Transgene confirms the potential of its two innovative platforms
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
Transgene to present new positive preliminary Phase I data on TG4050
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
Transgene and BioInvent Announce Poster Presentation on BT-001
Transgene appoints Steven Bloom as Chief Business Officer
Transgene appoints Steven Bloom as Chief Business Officer
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
Transgene announces Financial Calendar for 2022
Transgene Announces Financial Calendar for 2022
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
